Changli Wang

Shaanxi University of Chinese Medicine — China

Medicine · Health Sciences

17h-index5.4kcitations53works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(44), Lung Cancer Diagnosis and Treatment(28), Lung Cancer Research Studies(18), Gastric Cancer Management and Outcomes(8), Colorectal Cancer Treatments and Studies(7)

Publications53 total

Extraction and purification, structural characteristics, biological activities, applications, and quality control of Aloe vera polysaccharides: A review
International Journal of Biological Macromolecules·2025· 2 cited
Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis
BMC Medicine·2025· 2 citedOpen Access
Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
Annals of Surgical Oncology·2024· 3 cited
[Retracted] lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling
Oncology Reports·2024Open Access
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Nature Cancer·2024Open Access
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Nature Cancer·2023· 31 cited
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
Journal of Cancer Research and Clinical Oncology·2023· 9 citedOpen Access
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.
Journal of Clinical Oncology·2023· 21 cited
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Signal Transduction and Targeted Therapy·2023· 74 citedOpen Access
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Cancer Communications·2022· 54 citedOpen Access
Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
Frontiers in Oncology·2022· 3 citedOpen Access
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
JTO Clinical and Research Reports·2021· 34 citedOpen Access
Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.
Journal of Clinical Oncology·2021· 10 cited
CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.
Journal of Clinical Oncology·2021· 26 cited
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
Translational Lung Cancer Research·2021· 17 citedOpen Access
Macroseismic intensity attenuation in western China
Journal of Seismology·2021· 4 cited
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Frontiers in Oncology·2020· 2 citedOpen Access
Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis
Translational Lung Cancer Research·2020· 17 citedOpen Access
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition)
Translational Lung Cancer Research·2019· 31 citedOpen Access
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
Journal of Clinical Oncology·2019· 260 cited
page 1 of 3Next →

Frequent Co-authors

Yi‐Long Wu(11), Shucai Zhang(9), Ying Cheng(8), Yuankai Shi(8), Bin Zhang(8), Zhenfa Zhang(8), Xiuyi Zhi(7), Yue Yang(7), Ziping Wang(7), Jifeng Feng(6), Dongsheng Yue(6), Chun Chen(6), Lin Xu(6), Jianying Zhou(6), Xiaoqing Liu(6), Caicun Zhou(5), Gongyan Chen(5), Jie Wang(5), Chunhong Hu(5), Qun Wang(5)